Dako repositions for growth

Dako has repositioned itself for growth following its acquisition by leading private equity group EQT last year.

The new ownership has supported Dako programmes and also implemented new initiatives that include a new workflow strategy and a number of supporting product launches.

Dako also strengthened several management positions and, with a clear strategic focus, is repositioned to capture future growth in the market for cancer diagnostics.

Patrik Dahlen, chief executive and president of Dako, said that 2007 was a year of strategic importance.

"We have succeeded very well in creating Dako’s core focus on solutions for cancer diagnostics by innovative thinking, customer focus, and divestiture of non-core activities.

"Our recent launches and the solutions we have in the pipeline are expected to raise the standards in cancer diagnostics for the benefit of doctors and cancer patients needing fast and accurate answers," he said.

Dako’s sales for 2007 amounted to DKK 1,543 million (£164m) up by one per cent from the previous year.